

Elutia (NASDAQ:ELUT) sells SimpliDerm to Cellution Biologics for up to $11M to boost its balance sheet ahead of the NXT-41x launch.
You can purchase shares of Elutia (NASDAQ:ELUT) through any online brokerage.
Other companies in Elutia’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Elutia has a consensus price target of $7.00.
The stock price for Elutia (NASDAQ: ELUT) is $0.825 last updated October 26, 2026 at 9:30 AM EDT.
There are no upcoming dividends for Elutia.
Elutia does not have any upcoming earnings scheduled.
There is no upcoming split for Elutia.
Elutia is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include...